본문 바로가기

Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q4Scopus Q2
저널
UROLOGIA INTERNATIONALIS102(1) · pp.27 · 2019
피인용
Web of Science 44Scopus 50
FWCI (Scopus)
4.76
JCR IF
JCR 2018 1.401
ISSN
0042-1138

저자

  1. 김성장제1저자교신저자Department of Nuclear Medicine, College of Medicine, Pusan National University, Yangsan, South Korea
  2. Lee, Sang-WooDepartment of Nuclear Medicine, Kyungpook National University Medical Center, School of Medicine, Daegu, South Korea
  3. 하홍구Department of Urology, Pusan National University Hospital, Busan, South Korea

초록

Introduction: We aimed to assess the diagnostic accuracy of radiolabeled prostate-specific membrane antigen positron emission tomography (PSMA PET) or positron emission tomography/computed tomography (PET/CT) for primary lymph node (LN) staging in newly diagnosed intermediate to high-risk prostate cancer (PCa) patients, Material and Methods: The MEDLINE, PubMed, EMBASE, and Cochrane Library database from the earliest available date of indexing through May 31, 2018, were searched for studies evaluating the diagnostic performance of radiolabeled PSMA PET or PET/CT for primary LN staging in newly diagnosed intermediate to high-risk PCa. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. Results: Across 6 studies (298 patients), the pooled sensitivity was 0,71 (95% CI 0.59-0.81) and a pooled specificity of 0.95 (95% CI 0.87-0.99). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 15,6 (95% CI 5.6-43.0) and negative likelihood ratio (LR-) of 0.30 (95% CI 0.21-0.43). The pooled diagnostic odds ratio (DOR) was 51 (95% CI 21-126), Conclusion: Radiolabeled PSMA PET/CT shows a moderate sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed intermediate to high-risk PCa. (C) 2018 S. Karger AG, Basel

키워드

Positron emission tomographyPositron emission tomography/computed tomographyProstate cancerProstate-specific membrane antigenGA-68-PSMA PET/CTTEST ACCURACYEXPRESSIONMETASTASESPSMAADENOCARCINOMASENSITIVITYBIAS

식별자

Scopus EID
2-s2.0-85054486126
WoS UID
000456670200004